0.210
0.000
(0.00%)
May 22 - Close
OTCMKTS
data delayed by 15 mins -
Disclaimer
Currency in USD
| Range | - |
| 52 week | 0.20 - 0.96 |
| Open | - |
| Vol / Avg. | 0.00/1,074.00 |
| Mkt cap | 314,839.00 |
| P/E | - |
| Div/yield | - |
| EPS | -11.92 |
| Shares | 1.50M |
| Beta | 1.33 |
| Inst. own | 8% |
Key stats and ratios
| Q3 (Sep '11) | 2010 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -170.67% | -93.78% |
| Return on average equity | -326.02% | -191.87% |
| Employees | 20 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 530 300 Elliott Avenue West
SEATTLE, WA 94111
United States - Map
+1-206-2817001 (Phone)
+1-206-2843181 (Fax)
SEATTLE, WA 94111
United States - Map
+1-206-2817001 (Phone)
+1-206-2843181 (Fax)
Website links
External links
Advertisement
Description
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of oncology products to impact the lives of people with cancer. It develops picoplatin, a platinum-based chemotherapeutic agent that is in clinical development for multiple cancer indications, treatment combinations and by two routes of administration. The Company has offices in San Francisco, California; and Seattle, Washington in United States.
Officers and directors
| Ronald A. Martell | Chairman of the Board | |
| Robert S. Basso | Independent Director | |
| Frederick Craves PhD | Independent Director | |
| Carl S. Goldfischer M.D. | Independent Director | |
| Robert M. Littauer | Independent Director | |
| David R. Stevens Ph.D. | Independent Director |